scholarly journals Acute progression of congestive heart failure during paroxysmal supraventricular tachycardia in a patient without structural heart disease

2010 ◽  
Vol 1 (3) ◽  
pp. e133-e136 ◽  
Author(s):  
Seiichiro Matsuo ◽  
Teiichi Yamane ◽  
Mika Hioki ◽  
Ryohsuke Narui ◽  
Keiichi Ito ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Heart Disease ◽  
Supraventricular Tachycardia ◽  
Structural Heart Disease ◽  
Paroxysmal Supraventricular Tachycardia

Cardiovascular imaging in chronic kidney disease

ESC CardioMed ◽  
2018 ◽  
pp. 987-993
Author(s):  
Victoria Delgado
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Congestive Heart Failure ◽  
Heart Disease ◽  
Kidney Disease ◽  
Renin Angiotensin System ◽  
Structural Heart Disease ◽  
Cardiovascular Imaging ◽  
Traditional Risk Factors ◽  
Artery Disease

Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality. Congestive heart failure, coronary artery disease (CAD), cardiac arrhythmias and valvular heart disease are the most prevalent cardiovascular diseases in patients with CKD and account for 50% of all-cause mortality of patients with end stage renal disease.1 Particularly, congestive heart failure is the most prevalent cardiovascular condition in CKD patients and its prevalence increases as the kidney function declines. Pressure overload, as a consequence of long-standing hypertension and vascular stiffness, volume overload and CKD-related non-hemodynamic factors, such as inappropriate activation of the renin-angiotensin system, inflammation and stimulation of pro-hypertrophic and profibrogenic factors, are the main pathophysiological drivers of congestive heart failure.1 These factors along with a greater prevalence of traditional risk factors have been also associated to the pathogenesis of coronary plaque formation and rupture and reduced coronary flow reserve, peripheral artery disease and stroke. For the clinical cardiologist, the evaluation of CKD patients comprises the following areas:1. Is there structural heart disease? 2. Is there CAD?3. Atrial fibrillation and associated risk of embolic stroke4. Risk of sudden cardiac death (SCD)This section provides an overview on the use of multimodality cardiovascular imaging to diagnose and manage these cardiovascular complications.

Hypoglycemia Associated With Propranolol

PEDIATRICS ◽  
1973 ◽  
Vol 51 (6) ◽  
pp. 1085-1087
Author(s):  
John T. McBride ◽  
Margaret C. McBride ◽  
Peter H. Viles
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Heart Disease ◽  
Side Effects ◽  
Oral Intake ◽  
Blocking Agent ◽  
Paroxysmal Supraventricular Tachycardia ◽  
Drug Of Choice ◽  
Adrenergic Blocking

The beta-adrenergic blocking agent, propranolol, has been recommended for both immediate treatment and long-term control of cyanotic spells in children with tetralogy of Fallot.1 It has also been suggested as the second drug of choice, after digitalis, in the management of paroxysmal supraventricular tachycardia.2 The use of propranolol in children with heart disease thus is increasing. We would like to call attention to the possible occurrence of hypoglycemia during periods of restricted oral intake in children receiving propranolol. The most frequently cited side effects of propranolol are bronchospasm, bradycardia, hypotension, and congestive heart failure.3 Although not usually considered a side effect, hypoglycemia has been reported.4,5

scholarly journals Paroxysmal Supraventricular Tachycardia in Children : The Role of Infectious Diseases and Its Relationship to Serum Enzyme

2018 ◽  
Vol 29 (9-10) ◽  
pp. 173-81
Author(s):  
A. Samik Wahab
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Supraventricular Tachycardia ◽  
Lactic Dehydrogenase ◽  
First Episode ◽  
Paroxysmal Supraventricular Tachycardia ◽  
First Year ◽  
Antiarrhythmic Agents ◽  
One Year

The records of 28 children whose first episode of paroxysmal supraventricular tachycardia occurred before 12 years (median age 10 months) were reviewed. There were 17 males and 11 females. In 17 cases the first attack occurred before the first year and in 11 of these it occurred after the first year. One case had congenital heart disease (ASD). The WPW syndrome was diagnosed in 3 cases. When first seen, most of the infants presented with signs of incipient or manifest congestive heart failure. In almost ninetenth fo cases rhere was an increased of serum enzymes (lactic dehydrogenase, creatinephosphokinase  and glutamic oxaloaccetic transaminase. Digitals was effective against congestive heart failure and when continued, might prevent failure during subsequent attacks. Antiarrhythmic agents other than digitals were not used. It is recommended to continue digitalis treatment for at least one year in all patients with SVT, whether or not the first episode terminated spontaneously.

Early Surgical Intervention for Infective Endocarditis

2002 ◽  
Vol 10 (4) ◽  
pp. 298-301 ◽  
Author(s):  
Hong Sheng Zhu ◽  
Pei Yan Yao ◽  
Jia Hao Zheng ◽  
A Thomas Pezzella
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Heart Disease ◽  
Infective Endocarditis ◽  
Complex Disease ◽  
Surgical Intervention ◽  
Elective Surgery ◽  
Postoperative Bleeding ◽  
Arterial Embolization ◽  
Early Surgical Intervention

Infective endocarditis remains a serious and complex disease with significant morbidity and mortality. Sixty cases of infective endocarditis were retrospectively reviewed, consisting of 41 males and 19 females aged 7 to 50 years (mean, 30 years). Congenital heart disease was diagnosed in 19 of the patients and rheumatic heart disease in 41. Congestive heart failure occurred in 36 and systemic embolism in 8 cases. Blood cultures were positive in only 21.7% of the cases, while vegetations were detected by 2-dimensional echocardiography in 70%. Elective surgery was performed in 57 patients and emergent operation for systemic arterial embolization and/or intractable congestive heart failure in 3 patients. Two patients required reoperation for postoperative bleeding. All but 2 patients had been followed up for 6 to 160 months with no evidence of reinfection. Three patients with mechanical valve implantation later died of intracranial bleeding due to over-anticoagulation. The remaining 55 resumed normal activity. The encouraging outcomes were the result of an aggressive diagnostic approach and early surgical intervention.

scholarly journals Additive beneficial effects of beta blockers in the prevention of symptomatic heart failure

2016 ◽  
Vol 72 (1) ◽  
Author(s):  
Alberto Genovesi Ebert ◽  
Furio Colivicchi ◽  
Marco Malvezzi Caracciolo ◽  
Carmine Riccio
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Heart Disease ◽  
Beta Blockers ◽  
Structural Heart Disease ◽  
Symptomatic Heart Failure ◽  
Post Hoc Analysis ◽  
Lv Dysfunction ◽  
History Of ◽  
Post Hoc

The prevention of symptomatic heart failure represents the treatment of patients in the A and B stages of AHA/ACC heart failure classification. Stage A refers to patients without structural heart disease but at risk to develop chronic heart failure. The major risk factors in stage A are hypertension, diabetes, atherosclerosis, family history of coronary artery disease and history of cardiotoxic drug use. In this stage, blockers hypertension is the primary area in which beta blockers may be useful. Beta blockers seem not to be superior to other medication in reducing the development of heart failure due to hypertension. Stage B heart failure refers to structural heart disease but without symptoms of heart failure. This includes patients with asymptomatic valvular disease, asymptomatic left ventricular (LV) dysfunction, previous myocardial infarction with or without LV dysfunction. In asymptomatic valvular disease no data are available on the efficacy of beta blockers to prevent heart failure. In asymptomatic LV dysfunction only few asymptomatic patients have been enrolled in the trials which tested beta blockers. NYHA I patients were barely 228 in the MDC, MERIT and ANZ trials altogether. The REVERT trial was the only trial focusing on NYHA I patients with LV ejection fraction less than 40%. Metoprolol extended release on top of ACE inhibitors ameliorated LV systolic volume and ejection fraction. A post hoc analysis of the SOLVD Prevention trial demonstrated that beta blockers reduced death and development of heart failure. Similar results were reported in post MI patients in a post hoc analysis of the SAVE trial (Asymptomatic LV failure post myocardial infarction). In the CAPRICORN trial about 65% of the patients were not taking diuretics and then could be considered asymptomatic. The study revealed a reduction in mortality and a non-significant trend toward reduction of death and hospital admission for heart failure. Conclusions: beta blockers are not specifically indicated in stage A heart failure. On the contrary, in most of the stage B patients, and particularly after MI, beta blockers are indicated to reduce mortality and, probably, also the progression toward symptomatic heart failure.

Sign in / Sign up

Export Citation Format

Share Document